Drugs / Ipamorelin
Ipamorelin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01280344 | Apr 2011 → Jun 2013 | intestinal dysmotility syndrome | Helsinn Therapeutics (U.S.), Inc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00672074 Comparator | Apr 2008 → Dec 2009 | ileus | Helsinn Therapeutics (U.S.), Inc | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ipamorelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00672074 ↗ |
| Known as | Aib-his-d-2-nal-d-phe-lys-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58547 ↗ |
| Known as | Ipamorelina | ChEMBL registry synonym — accepted as the source's own label CHEMBL58547 ↗ |
| Known as | Ipamoreline | ChEMBL registry synonym — accepted as the source's own label CHEMBL58547 ↗ |
| Known as | NNC 26-0161 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58547 ↗ |
| Action | Activate | “the ghrelin-receptor agonist ipamorelin” PMID 25331030 ↗ Oct 2014 |
| Modality | Protein / enzyme biologic | — CHEMBL58547 ↗ |
| Route | Intravenous | “The intervention was intravenous infusions of 0.03-mg/kg ipamorelin vs placebo twice daily, on postoperative day 1 to 7 or hospital discharge.” PMID 25331030 ↗ Oct 2014 |